Teleflex Incorporated · Healthcare · Medical Instruments & Supplies
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$132.70
+$2.48 (+1.90%) 12:14 PM ET
Prev closePrevC$130.22
OpenOpen$133.25
Day highHigh$133.25
Day lowLow$128.78
VolumeVol378,760
Avg volAvgVol764,716
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$5.76B
P/E ratio
-6.51
FY Revenue
$1.99B
EPS
-20.38
Gross Margin
56.24%
Sector
Healthcare
AI report sections
BULLISH
TFX
Teleflex Incorporated
Teleflex’s share price has recently rebounded toward the upper half of its 52-week range with bullish short-term technical momentum despite negative 6–12 month returns. Fundamentally, the company combines solid revenue growth and healthy free cash flow generation with deeply negative net income and returns on capital. Valuation appears moderate on sales and book value multiples but is tempered by loss-making earnings and elevated leverage, while short interest and recent activist headlines point to a heightened risk and sentiment backdrop.
AI summarized at 12:16 AM ET, 2026-04-01
AI summary scores
INTRADAY:63SWING:55LONG:38
Volume vs average
Intraday (cumulative)
+44% (Above avg)
Vol/Avg: 1.44×
RSI
73.39(Overbought)
Overbought (>70)
0255075100
MACD momentum
Intraday
+0.05 (Strong)
MACD: 0.07 Signal: 0.02
Short-Term
+1.40 (Strong)
MACD: 4.01 Signal: 2.60
Long-Term
+1.25 (Strong)
MACD: 4.70 Signal: 3.45
Intraday trend score
78.79
LOW63.79HIGH81.79
Latest news
TFX•12 articles•Positive: 6Neutral: 4Negative: 2
NegativeGlobeNewswire Inc.• Portnoy Law Firm
Teleflex Incorporated Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated a securities fraud investigation into Teleflex Incorporated following a 13.06% stock price decline on January 8, 2026. The sharp drop was triggered by the sudden departure of CEO Liam Kelly from his roles as Chairman, President, and Chief Executive Officer, creating investor concerns about leadership continuity and strategic direction.
The company experienced a significant 13.06% stock price decline following the sudden and complete departure of its top executive (Chairman, President, and CEO) effective immediately. This abrupt leadership transition created investor uncertainty and loss of confidence, resulting in substantial shareholder value erosion and triggering a securities fraud investigation.
NegativeBenzinga• Vandana Singh
Activist Investor Urges Teleflex To Engage Potential Buyers
Irenic Capital, holding a 2% stake in Teleflex, has pressured the board to engage with potential acquirers to maximize shareholder value. The activist investor highlights a 73% shareholder return decline over five years and criticizes the board's long tenure and lack of open market stock purchases. Teleflex shares rose 5.37% on the news, though technical indicators show mixed momentum with bearish MACD signals and a neutral RSI.
Despite short-term stock price gains from activist pressure, the company faces significant headwinds including a 73% shareholder return decline over five years, 16.62% decline over the past 12 months, bearish MACD signals, and weak Benzinga Edge rankings across value, growth, and momentum pillars. The activist campaign indicates fundamental operational and strategic challenges.
PositiveBenzinga• Piero Cingari
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100 officially entered correction territory, down over 10% from January highs. The decline was driven by geopolitical tensions with Iran rejecting ceasefire options, surging crude oil prices, deteriorating consumer sentiment, and rising inflation expectations. The 30-year Treasury yield climbed to 4.958%, threatening to breach 5% for the first time since July 2025, while the Fed rate hike probability by December jumped to nearly 50%.
Top gainer with 5.39% gain, benefiting from defensive sector rotation
PositiveGlobeNewswire Inc.• Sns Insider
Pulmonary Artery Catheter Market Size to Reach USD 1.97 Billion by 2035 Caused by the Surging Critical Care Procedures Globally
The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.
Listed as a key manufacturer in the PAC market, which is experiencing growth from expanding ICU capacities and increasing cardiovascular surgeries globally.
NeutralGlobeNewswire Inc.• Sns Insider
Synthetic Absorbable Sutures Market Size to Hit USD 4.36 Billion by 2033, Driven by Rising Surgical Volumes and Minimally Invasive Procedures – SNS Insider
The global synthetic absorbable sutures market is valued at USD 2.51 billion in 2025 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 7.19%. Growth is driven by rising surgical volumes, increasing adoption of minimally invasive procedures, and advancements in polymer technology. However, higher costs compared to conventional sutures may limit adoption in cost-sensitive markets. North America leads with 40% market share, while Asia Pacific is expected to grow fastest at 9.31% CAGR.
Included as a major player in the market but no specific recent developments or strategic initiatives mentioned in the article.
PositiveGlobeNewswire Inc.• Sns Insider
Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider
The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.
Listed as a major player in the growing catheters market, expected to benefit from increased adoption of advanced catheterization techniques and rising procedure volumes.
NeutralGlobeNewswire Inc.• Sns Insider
Pulmonary Function Testing Market Size to Hit USD 5.66 Billion by 2033, Growing at a CAGR of 6.65% - SNS Insider
The global pulmonary function testing market is projected to grow from USD 3.39 billion in 2025 to USD 5.66 billion by 2033, with a CAGR of 6.65%. Growth is driven by rising prevalence of chronic respiratory diseases, an aging population, and technological advancements in diagnostic devices. The U.S. market is expected to expand from USD 1.03 billion to USD 1.67 billion during the same period. Asia Pacific is anticipated to experience the fastest regional growth at 7.27% CAGR.
TFXpulmonary function testingrespiratory diseasesCOPDasthmaspirometrydiagnostic deviceshealthcare market
Sentiment note
Listed as a major player in the market but no specific recent developments or company-specific information provided in the article.
PositiveGlobeNewswire Inc.• Delveinsight
Global Disposable Endoscopes Market to Accelerate at a CAGR of ~10% by 2032 as Healthcare Shifts Toward Infection-Free Diagnostic Solutions | DelveInsight
The global disposable endoscopes market is expected to grow from USD 2.6 billion in 2024 to USD 5.7 billion by 2032, driven by healthcare providers' focus on infection control, minimally invasive procedures, and technological advancements. North America leads the market, while Asia-Pacific is expected to experience the fastest growth. Key players include Olympus, Boston Scientific, and Ambu, with recent developments including product launches and manufacturing expansions.
Identified as a leading company in the disposable endoscopes market, positioned to benefit from the market's strong growth trajectory driven by infection control priorities and technological advancements.
PositiveGlobeNewswire Inc.• Lars Rasmussen
Coloplast annoncerer ændringer i ledelsesteamet
Coloplast announces leadership transitions, with Dorthe Rønnau leaving People & Culture and Tommy Johns retiring from Urologi. Kevin Hardage will join as new Urologi leader, bringing extensive medtech experience.
Company mentioned as previous employer of incoming executive Kevin Hardage, suggesting talent pipeline strength
NeutralGlobeNewswire Inc.• Researchandmarkets.Com
U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF Solutions
The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.
Mentioned as a market participant without specific performance details
NeutralGlobeNewswire Inc.• Sns Insider
Intravenous Catheters Market Size to Hit USD 16.47 Billion by 2032, at 6.9% CAGR | Report by SNS Insider
The global intravenous catheters market is projected to grow from USD 9.06 billion in 2024 to USD 16.47 billion by 2032, driven by rising chronic disease prevalence and increasing demand for outpatient and home-based IV therapies.
Mentioned as a market player without specific performance details
PositiveBenzinga• Globe Newswire
Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business
Teleflex has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million, expanding its global presence in the cath lab and peripheral intervention market with a comprehensive portfolio of medical technologies.
The company is strategically expanding its medical technology portfolio, gaining new product lines, and expecting revenue growth and earnings accretion from the acquisition
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal